Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00759356 · ClinicalTrials.gov registry record · Phase 1
Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fed Conditions
A Phase 1 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00759356 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 36 participants.
The verdict
NCT00759356, a Phase 1 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The objective of this single-dose, open-label, randomized, two-period crossover study was to compare the rate of absorption and oral bioavailability of a test formulation of morphine sulfate 200 mg sustained-release capsules manufactured by Alpharma Branded Products Division Inc. to an equivalent oral dose of the commercially available reference product, KADIAN 2 x 100 mg capsules manufactured by Alpharma Branded Products Division Inc. when administered under fed conditions.
Interventions
- DRUG morphine sulfate sustained-release capsules
- DRUG KADIAN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2004-08 |
| Est. Completion | 2004-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00759356
The ClinicalTrials.gov registry entry for NCT00759356 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which morphine sulfate sustained-release capsules is the first listed.
NCT00759356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00759356 about?
NCT00759356 is a clinical study titled "Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fed Conditions". The objective of this single-dose, open-label, randomized, two-period crossover study was to compare the rate of absorption and oral bioavailability of a test formulation of morphine sulfate 200 mg sustained-release capsules manufactured by Alpharma Branded Products Division Inc. to an equivalent or...
What is the current status of trial NCT00759356?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2004-08. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00759356?
The interventions under investigation include: morphine sulfate sustained-release capsules (DRUG), KADIAN (DRUG).
Who is sponsoring clinical trial NCT00759356?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.